13 5月 2021 by admin in UncategorizedComments Preclinical Data of Arcellx’s Novel Synthetic CAR-T Binding Domain Presented at the 2021 ASGCT Annual Meeting and the 2021 PEGS Summit
12 5月 2021 by admin in UncategorizedComments Citrine Medicine Announces Strategic Partnership to bring Efmody® to China for Use in Adrenal Insufficiency (AI), including Congenital Adrenal Hyperplasia (CAH)
10 5月 2021 by admin in UncategorizedComments Design Therapeutics Announces Business Highlights and Reports First Quarter 2021 Financial Results
10 5月 2021 by admin in UncategorizedComments Crescendo Biologics further strengthens leadership team with appointment of Dr Michael Booth as Chief Financial Officer
06 5月 2021 by admin in UncategorizedComments Syros Reports First Quarter 2021 Financial Results and Highlights Key Accomplishments and Upcoming Milestones
19 4月 2021 by admin in UncategorizedComments Crescendo Biologics and IAG partner to support the clinical development of CB307 with advanced imaging analysis technology
19 4月 2021 by admin in UncategorizedComments Citrine Medicine and Sinopharm Group Announce Strategic Partnership to Broaden and Accelerate Access to Rare Disease Drugs in China
16 4月 2021 by admin in UncategorizedComments New data demonstrate that Humabodies® are highly effective in generating monospecific and bispecific CAR-T cells to target solid tumours
13 4月 2021 by admin in UncategorizedComments Arcellx Closes $115 Million Series C Financing to Advance its Pipeline of Adaptive and Controllable Cell Therapies
13 4月 2021 by admin in UncategorizedComments Adicet Bio Appoints Dr. Blake Aftab as Vice President of Research
10 4月 2021 by admin in UncategorizedComments NextCure Presents Preclinical Data for NC762 at American Association for Cancer Research (AACR)
06 4月 2021 by admin in UncategorizedComments Arcellx Announces FDA Clearance of IND Application for ACLX-001, a Controllable Cell Therapy Utilizing the Company’s ARC-SparX Platform, for the Treatment of Multiple Myeloma
30 3月 2021 by admin in UncategorizedComments Design Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters
26 3月 2021 by admin in UncategorizedComments Design Therapeutics Announces Pricing of Initial Public Offering
22 3月 2021 by admin in UncategorizedComments Innoforce Pharmaceuticals Completes 625M CNY ($96M) Series A Financing
11 3月 2021 by admin in UncategorizedComments Adicet Reports Fourth Quarter and Full Year 2020 Financial results
10 3月 2021 by admin in UncategorizedComments Adicet Bio Announces Initiation of its First-in-Human Phase 1 Trial of ADI-001 for the Treatment of B
04 3月 2021 by admin in UncategorizedComments Syros Reports Fourth Quarter and Full Year 2020 Financial Results
04 3月 2021 by admin in UncategorizedComments NextCure Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial
03 3月 2021 by admin in UncategorizedComments Tempest Therapeutics Announces Clinical Collaboration with Roche to Advance TPST-1120 into a Randomized Combination Study in First-line Hepatocellular Carcinoma
02 3月 2021 by admin in UncategorizedComments Innoforce and dMed Collaborate to Accelerate the Development of Innovative Therapeutics
16 2月 2021 by admin in UncategorizedComments Adicet Bio, Inc. Announces Closing of $152 Million Public Offering and Concurrent Private
10 2月 2021 by admin in UncategorizedComments Adicet Bio, Inc. Announces Pricing of $135 Million Public Offering of Common Stock and Concurrent
09 2月 2021 by admin in UncategorizedComments Adicet Bio, Inc. Announces Proposed Public Offering of Common Stock and Concurrent Private
26 1月 2021 by admin in UncategorizedComments Arcellx Appoints Rami Elghandour as Chairman and Chief Executive Officer
